Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Core Insights - Celularity is collaborating with Genting Berhad to introduce placenta-derived allogeneic stem cell therapeutics in the Asia Pacific region [1][4] - Genting Berhad has commenced construction of Fontaine Vitale, a wellness and health center in Bali, Indonesia, which will utilize Celularity's products [1][2] - The Asia Pacific stem cell market is projected to grow from USD 3.0 billion in 2024 to USD 7.2 billion by 2030, with a CAGR of 16.4% [3] Company Overview - Celularity Inc. specializes in regenerative medicine, focusing on advanced biomaterial products and placenta-derived cell therapies targeting aging-related diseases, cancer, and immune disorders [5] - The company utilizes mesenchymal-like adherent stromal cells (MLASCs), CAR T-cells, and natural killer (NK) cells in its therapeutic programs [5] Market Context - The Asia Pacific region accounts for 16.8% of the global stem cell market and is expected to experience the highest growth rate globally [3] - Increased investment in stem cell technologies and therapies is driven by a growing emphasis on research and development in regenerative medicine within the region [3]